Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients

National Taiwan University

Status: Unknown

Conditions: Squamous Cell Carcinoma of the Oral Cavity

Treatments: Dietary Supplement: β-glucan

Study type: Interventional

Funder types: Other

Identifiers

NCT04387682

201701065RIPB

Details and patient eligibility

About

Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunity for OSCCs reduces the recurrence rate or improves survival. We first identified CD33+/CD11b+/HLA-DR-/low/CD14+/- as myeloid-derived suppressor cell (MDSC) surface markers by using flow cytometry to compare the MDSC frequency of OSCCs with blood samples from healthy donors (HDs). We then re-confirmed the suppression of T cell proliferation and function achieved by co-culturing with OSCC-educated MDSCs. We subsequently explore whether using particulate β-glucan as a food-grade supplement promotes the human immune system via subversion of immune modulatory MDSCs. Lastly, we correlated clinicopathological parameters with MDSCs and β-glucan administration to examine anti-tumor immunity, and to predict the therapeutic effect and prognosis in OSCC patients..

Full description

Oral squamous cell carcinoma (OSCC) has the highest annual increase in the rate of death among the top 10 leading cancers in Taiwan. This research aimed to explore whether increased anti-tumor immunity for OSCCs reduces the recurrence rate or improves survival. We first identified CD33+/CD11b+/HLA-DR-/low/CD14+/- as myeloid-derived suppressor cell (MDSC) surface markers by using flow cytometry to compare the MDSC frequency of OSCCs with blood samples from healthy donors (HDs). We then re-confirmed the suppression of T cell proliferation and function achieved by co-culturing with OSCC-educated MDSCs.

Clinically, we enrolled 100 OSCC patients and 30 HDs to demonstrate a significantly higher MDSC frequency in OSCC candidates than HDs. To determine whether using β-glucan as a food-grade supplement promotes the immune system of OSCC patients, we further allocated OSCC patients with and without pre-surgical administration of whole glucan particle β-glucan to groups II and III, respectively (with group I being the HDs).

We will explore whether using particulate β-glucan as a food-grade supplement promotes the human immune system via subversion of immune modulatory MDSCs. Lastly, we correlated clinicopathological parameters with MDSCs and β-glucan administration to examine anti-tumor immunity, and to predict the therapeutic effect and prognosis in OSCC patients.

Enrollment: 130 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Oral squamous cell carcinoma (OSCC) subjects without other cancer diagnosis
• healthy donors (HDs)

Exclusion criteria

• pregnant woman

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Single Blind

---

130 participants in 3 patient groups

OSCC subjects with β-glucan supplement

Other group

Description:

Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan

Treatment:

Dietary Supplement: β-glucan

Healthy donors

No Intervention group

Description:

healthy donors without pre-surgical administration of whole glucan particle β-glucan

OSCC subjects without β-glucan supplement

No Intervention group

Description:

Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan